Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.52 |
| ▸ | DRD2 | P14416 | 9/20 | 0.52 |
| ▸ | DRD3 | P35462 | 6/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8573299 | 0.88 | CCNA2 (0.47) | DRD4DRD2DRD3USP30MKNK1 | |
| SCHEMBL90870 | 0.84 | DRD4 (0.48) | DRD4DRD2DRD3MAPK8USP30 | |
| SCHEMBL90978 | 0.84 | DRD4 (0.48) | DRD4DRD2DRD3MAPK8USP30 | |
| SCHEMBL8579108 | 0.84 | MKNK1 (0.44) | DRD4DRD2DRD3MKNK1MKNK2 | |
| SCHEMBL2374222 | 0.81 | DRD4 (0.67) | DRD4DRD2DRD3USP30MKNK1 | |
| SCHEMBL91006 | 0.79 | MKNK1 (0.40) | DRD4DRD2DRD3USP30MKNK1 | |
| SCHEMBL90983 | 0.74 | DRD2 (0.50) | DRD4DRD2DRD3USP30MKNK1 | |
| SCHEMBL91004 | 0.73 | DRD4 (0.57) | DRD4DRD2DRD3MKNK1MKNK2 | |
| SCHEMBL90957 | 0.73 | MKNK1 (0.57) | DRD4MKNK1MKNK2MEN1KMT2A | |
| SCHEMBL91023 | 0.73 | MKNK1 (0.57) | DRD4DRD2DRD3MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | DRD4 577/4885DRD2 351/4885DRD3 352/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | DRD4 577/4885DRD2 351/4885DRD3 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.